1. Home
  2. ARVN vs GPRK Comparison

ARVN vs GPRK Comparison

Compare ARVN & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$6.79

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Logo Geopark Ltd

GPRK

Geopark Ltd

N/A

Current Price

$9.41

Market Cap

706.1M

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
GPRK
Founded
2015
2002
Country
United States
Colombia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
706.1M
IPO Year
2018
2009

Fundamental Metrics

Financial Performance
Metric
ARVN
GPRK
Price
$6.79
$9.41
Analyst Decision
Buy
Buy
Analyst Count
15
4
Target Price
★ $14.00
$11.23
AVG Volume (30 Days)
★ 859.5K
752.1K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
★ 1.14%
EPS Growth
★ 58.84
N/A
EPS
★ 0.88
N/A
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$5.67
$17.63
Revenue Next Year
N/A
$16.73
P/E Ratio
★ $7.78
$12.70
Revenue Growth
N/A
★ N/A
52 Week Low
$6.33
$6.84
52 Week High
$14.22
$13.13

Technical Indicators

Market Signals
Indicator
ARVN
GPRK
Relative Strength Index (RSI) 41.87 33.18
Support Level $6.74 $8.98
Resistance Level $7.85 $10.06
Average True Range (ATR) 0.47 0.40
MACD -0.03 -0.13
Stochastic Oscillator 27.06 18.78

Price Performance

Historical Comparison
ARVN
GPRK

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About GPRK Geopark Ltd

GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.

Share on Social Networks: